Skip to main content

Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly

In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson explained how his company uses new AI technology to develop drugs.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.